Researchers have developed lipid nanoparticles (LNPs) that cross the blood-brain barrier (BBB) and precisely target brain cells, a major step toward treating neurological diseases like Alzheimer's. By attaching short peptides to LNPs, scientists achieved targeted mRNA delivery to neurons and endothelial cells, avoiding invasive procedures. Peptides are smaller, more stable, and easier to use than antibodies, making them ideal for LNP-based therapies.
Researchers have developed lipid nanoparticles (LNPs) that cross the blood-brain barrier (BBB) and precisely target brain cells, a major step toward treating neurological diseases like Alzheimer's. By attaching short peptides to LNPs, scientists achieved targeted mRNA delivery to neurons and endothelial cells, avoiding invasive procedures. Peptides are smaller, more stable, and easier to use than antibodies, making them ideal for LNP-based therapies.
Share this Article
Recommended